团队总计成员8人，拥有正高级职称1人、博导 1名、副高职称 2人、中级职称 4 人。团队成员中 5人具有博士学位，其中包括北京市组织部“高创计划”青年拔尖人才入选者 1 人，北京市“科技新星” 1人，北京市优秀人才青年项目1 人，北京市医管局登峰项目 1 人，青苗项目1 人， 团队成员中在中华医学会结核病学分会、中国防痨协会、中国医促会结核病学分会中各分支机构中担任主任委员以上职务者 1 人次，委员 2 人次，青年委员2 人次。

逄宇是我校附属北京胸科医院细菌免疫室主任，北京市百千万人才工程入选者，北京市组织部“高创计划”青年拔尖人才入选者，北京市“科技新星”，是我校结核病分子流行病研究领域的学科带头人。经过多年的合作研究，集中进行了耐药结核分枝杆菌分子流行病及临床相关研究，围绕科学耐药结核病防治的框架，聚焦于本领域亟待解决的科学问题，集中攻关，取得了优异成绩，开创了临床为引导，基础为支撑，应用为目的的结核病分子流行病学研究方向。 团队目前已经与美国、英国、加拿大、荷兰、日本、韩国等国家合作开展了一系列结核病领域的国际合作研究。近 5 年来，承担国家重大项目、国家自然科学基金等国家级项目 10 余项，在《European Respiratory Journal》、 《Nature Communication》、 《Clinical Infectious Diseases》等刊物上发表 SCI 论文100 余篇，获省部级奖励 6 项。

长期以来， 团队关注青年人才培养，指导青年人才课题设计申报、开展科学实验及研究论文撰写等工作，近 3 年以来，总计有 4 名青年人才入选单位结核病学科骨干计划， 2 名入选单位结核病培育计划， 4 人顺利晋升高级职称。同时积极创造更多的国际合作研究机会，帮助 2 名人才赴日本和加拿大访问研究，拓展青年人才在研究领域的国际视野，积极鼓励、推荐和支持优秀的青年人才的全面发展。

1.202101-202412 HDAC6介导的自噬在结核抵抗者产生中的作用机制  国家自然科学基金委员会面上项目（55万）负责人

2.202301-202612  结核特异性记忆样NK细胞表面受体CRTAM介导NF-κB信号通路释放IFN-γ清除结核分枝杆菌的分子机制 国家自然科学基金委员会面上项目（52万）负责人

3.202101-202312  非结核分枝杆菌病  北京市医院管理中心扬帆重点专业（200万）负责人 

4.201901-202312 耐药结核病分子流行病学  北京市医院管理中心“登峰人才”培养计划（100万）负责人

5.202001-202212 北京地区广泛耐药结核时空传播规律及风险因素研究 首都卫生发展科研专项重点项目（70万）负责人

6.202101-202212 北京地区广泛耐药结核的传播规律及演化特征 北京市委人才局百千万人才工程项目（5.8万）负责人

7.202208-202508 老年人结核病患者免疫特征及其动态监测 广西自治区科技重大专项  （95.62万）子课题负责人  

1.202101-202412 HDAC6介导的自噬在结核抵抗者产生中的作用机制  国家自然科学基金委员会项目（55万）负责人

2.202101-202312  非结核分枝杆菌病  北京市医院管理中心扬帆重点专业（200万）负责人 

3.201901-202312 耐药结核病分子流行病学  北京市医院管理中心“登峰人才”培养计划（100万）负责人

4.202001-202212 北京地区广泛耐药结核时空传播规律及风险因素研究 首都卫生发展科研专项重点项目（70万）负责人

5.202101-202212 北京地区广泛耐药结核的传播规律及演化特征 北京市委人才局百千万人才工程项目（5.8万）负责人

6.202208-202508 老年人结核病患者免疫特征及其动态监测 广西自治区科技重大专项  （95.62万）子课题负责人  

一、重要奖项

1. 耐药结核病精准诊疗关键技术研究及推广应用  北京市科技进步二等奖  202209

2. DOTS-PLUS策略下耐药肺结核医防合作与新型诊断技术应用 陕西省科学技术奖三等奖 201912

3. 中华医学会结核病学分会2017年度杰出青年人才奖中华医学会结核病学分会2017年度杰出青年人才奖 无 201705

4. 吉林省结核病耐药监测技术平台的建立和耐药谱研究 吉林省科学技术奖 三等奖201611

5. 我国耐药结核病流行状况及关键防治技术的研究 中华预防医学会科学技术奖三等奖201601

6. 我国耐药结核病流行状况及关键防治技术的研究 中华医学会科技奖 二等奖 201412

7. 棉花纤维细胞伸长发育的基础研究 中华人民共和国教育部自然科学 一等奖 200901

二、重要学术论文

1. Yuhong Liu#,Jingtao Gao,Jian Du,WeiShu,Lu Wang,YufengWang,Zhongtan Xue,Liang Li*,Shaofa Xu*,Yu Pang*.Acquisitionof clofazimineresistance following bedaquiline treatment formultidrug-resistant tuberculosis.Int J Infect Dis. 2020,102:392-396.SCI

2. Fengmin Huo#,Yifeng Ma#,RongmeiLiu#,Liping Ma#,ShanshanLi,Guanglu Jiang,Fen Wang,Yuanyuan Shang,LinglingDong,Yu Pang*.Interpretationof Discordant Rifampicin Susceptibility TestResults Obtained Using GeneXpert vsPhenotypic Drug Susceptibility Testing.Open Forum Infect Dis.2020,7(8):ofaa279.SCI

3. Fengmin Huo#,Yifeng Ma#,Shanshan Li#,YiXue,YuanyuanShang,Lingling Dong,Yunxu Li,Yu Pang*.Specific gyrA Gene MutationsCorrelatewith High Prevalence of Discordant Levofloxacin Resistance inMycobacteriumtuberculosis Isolates from Beijing, China. J Mol Diagn.2020,22(9):1199-1204.SCI

4. Jun Fan#,Jun An#,Wei Shu#,FengminHuo,Shanshan Li,Fen Wang,ShibingQin*,Yu Pang*.Epidemiology of skeletaltuberculosis in Beijing, China: a 10-yearretrospective analysis of data. Eur JClin Microbiol Infect Dis.2020,39(11):2019-2025.SCI

5. Qian Liang#,Yuanyuan Shang#,FengminHuo,Yi Xue,Yunxu Li,LinglingDong,Shanshan Li*,Yu Pang*.Assessment of currentdiagnostic algorithm fordetection of mixed infection with Mycobacteriumtuberculosis and nontuberculousmycobacteria. J Infect Public Health.2020,13(12):1967-1971.SCI

6. Jun Wang#,Weijie Zhao#,RongmeiLiu#,Fengmin Huo,Lingling Dong,YiXue,Yufeng Wang,Zhongtan Xue,Liping Ma*,YuPang*.Rapid Detection ofEthambutol-Resistant Mycobacterium tuberculosis fromSputum by High-ResolutionMelting Analysis in Beijing, China. Infect DrugResist. 2020,20;13:3707-3713.SCI

7. Jingtao Gao#,Yi Pei#,XiaofengYan#,Guomin Shi#,Tongxin Li#,MengqiuGao#,Yuhong Liu,Yufeng Wang,Wei Shu,LiangLi*,Yu Pang*.Emergence ofnontuberculous mycobacteria infections duringbedaquiline-containing regimens inmultidrug-resistant tuberculosis patients.Int J Infect Dis.2020,100:196-198.SCI

8. Zhen Zhou#,Yujie Dong#,ChenghaiLi,Dongpo Wang,Yan Lv,PingxinLv*,Yu Pang*.Determining the optimal puncturesite of CT-guided transthoracicneedle aspiration biopsy for the diagnosis oftuberculosis. J Thorac Dis.2020,12(8):3987-3994..SCI

9. Yuhong Liu#,Mengqiu Gao#,Jian Du#,LuWang#,Jingtao Gao#,WeiShu,Yufeng Wang,Zhongtan Xue,Liang Li*,Yu Pang*.Reducedsusceptibility ofMycobacterium tuberculosis to bedaquiline duringantituberculosis treatment andits correlation with clinical outcomes in China.Clin Infect Dis. 2020,15:ciaa1002.SCI

10. Zhuo-Hong Yan#,Bing Zhao,YuPang,Xiao-Jue Wang ,Ling Yi,He-LinWang,Bin Yang ,Pan-Jian Wei,Hong-YanJia,Shu-Ping Li,Yan-Lin Zhao*,Hong-TaoZhang*,.Generation of mycobacteriallipoarabinomannan-specific monoclonalantibodies and their ability to identifymycobacterium isolates.. J MicrobiolImmunol Infect..2020,S1684-1182(20):30033-5.SCI

11. Hou J #, Pang Y# , Yang X , Chen T ,Yang H , Yang R , Chen L ,Xu L *.Outbreak of Mycobacterium tuberculosisBeijing Strain in a High School inYunnan, China.. Am J Trop Med Hyg.. 2020,Feb24:19-0533.SCI

12. Jianjie Wang#, Meilan Zhou, Zi Chen,Cong Chen, Gang Wu, YingpingZuo, Xin Ren, Zhuan Chen, Weihua Wang*， YuPang*.Survival of patients with multidrug-resistant tuberculosisin CentralChina: a retrospective cohort study. Epidemiol Infect.. 2020,Feb19:148:e50.SCI

13. Huo F #, Zhang F #, Xue Y , Shang Y ,Liang Q , Ma Y , Li Y ,Zhao L , Pang Y *.Increased prevalence oflevofloxacin-resistant Mycobacteriumtuberculosis in China is associated withspecific mutations within the gyrAgene. Int J Infect Dis.. 2020,Mar（92）:241-246.SCI

14. Ma Y #, Fan J #, Li S #, Dong L , Li Y, Wang F , Huo F , Pang Y* Qin S *.Comparison of Lowenstein-Jensen medium andMGIT culture system forrecovery of Mycobacterium tuberculosis from abscesssamples.. Diagn MicrobiolInfect Dis.. 2020,96(4):114969.SCI

15. Du J #， Shu W #，Liu Y #， Wang Y , Zhan Y , Yu K , Gao J ,Li L* , Pang Y*.Multicenter feasibility study to assess external qualitypanels for moleculardiagnostics for tuberculosis in China.. Eur J ClinMicrobiol Infect Dis..2020,39(2):339-343.SCI

16. Shu W #, Du J #, Liu Y#, Wang Y , HuoF, Jiang G , Li L* , Pang Y*.External quality control of phenotypic drugsusceptibility testing forMycobacterium tuberculosis in China.. Eur J ClinMicrobiol Infect Dis.. 2020,Jan 2:【未填写起止页码】.SCI

17. Dong W # , Li S # , Wen S # , Jing W ,Shi J , Ma Y , Huo F , GaoF *, Pang Y*, Lu J *.In Vitro Susceptibility Testingof GSK656 againstMycobacterium Species. Antimicrob Agents Chemother..2020,64(2):pii:e01577-19.SCI

18. Liu R #, Li J #, Tan Y #, Shang Y , LiY , Su B ， Shu W , Pang Y *, Gao M *, Ma L*.Multicenterevaluation of theacid-fast bacillus smear, mycobacterial culture, XpertMTB/RIF assay, andadenosine deaminase for the diagnosis of tuberculousperitonitis in China.. IntJ Infect Dis.. 2020,Jan;90:119-124.SCI

19. Yifeng Ma # , Jun Fan # , Shanshan Li #, Lingling Dong , YunxuLi , Fen Wang , Fengmin Huo , Yu Pang* , ShibingQin*.Comparison ofLowenstein-Jensen medium and MGIT culture system forrecovery of Mycobacteriumtuberculosis from abscess samples. Diagn. Microbiol.Infect. Dis. .2020,96(4):114969.SCI

20. Zhang F # , Li S# , Wen S, Zhang T,Shang Y , Huo F , Xue Y , LiL* , Pang Y *.Comparison of in vitroSusceptibility of Mycobacteria AgainstPA-824 to Identify Key Residues of Ddn,the Deazoflavin-Dependent Nitroreductasefrom Mycobacterium tuberculosis..Infect Drug Resist.. 2020,Mar11;13:815-822.SCI

21. Lin S #, Wei S , Zhao Y , Lin J *， PangY*.Epidemiology Of Human Pulmonary Infection WithNontuberculous Mycobacteria InSoutheast China: A Prospective SurveillanceStudy.. Infect Drug Resist..2019,Nov 12;12:3515-3521.SCI

22. Zhengwei Liua#, Huali Dong # , BeiBeiWua , Mingwu Zhanga , YeleiZhua , Yu Pang∗ , Xiaomeng Wang*.Isrifampin resistance areliable predictive marker of multidrug-resistant tuberculosisin China: Ameta-analysis of findings. J. Infect. . 2019,79(4):349-356.SCI

23. Fengmin Huo# , Jie Lu# , Zhaojing Zong,Wei Jing, Jin Shi ,Yifeng Ma , Lingling Dong , Liping Zhao , Yufeng Wang ,Hairong Huang ,YuPang*.Change in prevalence and molecular characteristics ofisoniazid-resistanttuberculosis over a 10-year period in China. BMC Infect.Dis. .2019,19(1):689.SCI

24. Jian Du#, Wei Shu, Yuhong Liu, YufengWang, Ying Zhan, KexinYu,Jingtao Gao, Liang Li*,Yu Pang*.Development andvalidation of externalquality assessment panels for mycobacterial culturetesting to diagnose tuberculosisin China. Eur. J. Clin. Microbiol. Infect.Dis.. 2019,38(10):1961-1968.SCI

25. Tingting Zhang,* Guanglu Jiang,* Shu’anWen,* Fengmin Huo, FenWang, Hairong Huang*,Yu Pang*.Para-aminosalicylic acidincreases thesusceptibility to isoniazid in clinical isolates of Mycobacteriumtuberculosis.Infect Drug Resist. 2019,12:825-829.SCI

26. Mingguan Lin# , Yeteng Zhong , ZhuolinChen, Chong Lin , Hua Pei, Wei Shu, Yu Pang*.High incidence of drug-resistantMycobacterium tuberculosisin Hainan Island, China. Trop. Med. Int. Health .2019,24(9):1098-1103.SCI

27. Qingtao Liang#, Yu Pang# , Yang Yang ,Hua Li , Chao Guo ,Xinting Yang, Xiaoyou Chen*.An improved algorithm for rapiddiagnosis of pleuraltuberculosis from pleural effusion by combined testingwith GeneXpert MTB/ RIFand an anti-LAM antibody-based assay. BMC Infect. Dis.. 2019,19(1):548.SCI

28. Hui Liu#, Fang Dong,Jinrong Liu,Jianhua Liu, Yu Pang, ShunyingZhao,Jie Lu*, Huimin Li*.Successful managementof Mycobacterium abscessuscomplex lung disease in an otherwise healthy infant.Infect Drug Resist .2019,12:1277-1283.SCI

29. Jing Wang#, Yu Pang#, Wei Jing#, WeiChen#,Ru Guo#,Xiqin Han,Limin Wu, Guangxu Yang, Kunyun Yang,Cong Chen, LinJiang,Chunkui Cai, Zhi Dou,Lijuan Diao,Hongqiu Pan, Jianyun Wang, Feifei Du,Tao Xu, Lixia Wang, RenzhongLi*,Naihui Chu*.Efficacy and safety ofcycloserine-containing regimens in thetreatment of multidrug-resistanttuberculosis: a nationwide retrospective cohortstudy in China. Infect DrugResist . 2019,12:763-770.SCI

30. Qiyao Chai#, Xudong Wang, Lihua Qiang,Yong Zhang, Pupu Ge, ZheLu, Yanzhao Zhong, Bingxi Li , Jing Wang , LingqiangZhang, Dawang Zhou , WeiLi, Wenzhu Dong, Yu Pang, George Fu Gao , Cui Hua Liu*.A Mycobacteriumtuberculosis surface protein recruits ubiquitin to triggerhost xenophagy. NatCommun. 2019,10(1):1973.SCI

31. Yu Pang # , Wei Jing # , Jie Lu# ,Zhaojing Zong , Fengmin Huo ,Lingling Dong , Guangming Dai , Yunxu Li ,Hairong Huang ⁎, Naihui Chu ⁎.No in vitro synergistic effect of bedaquiline combined withfluoroquinolones,linezolid, and clofazimine against extensively drug-resistanttuberculosis.Diagn. Microbiol. Infect. Dis. . 2019,94(4):361-364.SCI

32. Zhijian Zhanga# , Jie Lub# , YingzhenDua# , Fei Xie#, YufengWang, Baojun Suna *, Yu Pang,*.Comparison of in vitrosynergistic effect betweenclarithromycin or azithromycin in combination withamikacin againstMycobacterium intracellulare. J Glob Antimicrob Resist.2019,18:183-186.SCI

33. Shu’an Wen#, Wei Jing#, TingtingZhang#, Zhaojing Zong, Yi Xue,Yuanyuan Shang, Fen Wang,Hairong Huang*,NaihuiChu*, Yu Pang*.Comparison of invitro activity of the nitroimidazoles delamanidand pretomanid againstmultidrug-resistant and extensively drug-resistanttuberculosis. Eur. J. Clin.Microbiol. Infect. Dis. . 2019,38(7):1293-1296.SCI

34. Rongmei Liu#, Qian Liang#,YuanyuanShang#, Yifeng Ma, Fen Wang,Lingling Dong, Hairong Huang*, Mengqiu Gao*, YuPang*.GeneXpert of stool versusgastric lavage fluid for the diagnosis ofpulmonary tuberculosis in severely illadults. Infection.2019,47(4):611-616.SCI

35. Liu Y #, Pang Y , Du J , Shu W , Ma Y ,Gao J , Zhang L , Xu S* ,Li L *.An Overview of Tuberculosis-DesignatedHospitals in China, 2009-2015: ALongitudinal Analysis of National SurveyData.. Biomed Res Int.. 2019,Aug20;2019:9310917.SCI

36. Xu J#, Li P , Zheng S , Shu W , Pang Y*..Prevalence and riskfactors of pulmonary nontuberculous mycobacterialinfections in the ZhejiangProvince of China.. Epidemiol Infect. . 2019,Sep11;147:e269.SCI

37. H Duan(#); X Chen(#); Z Li(#); YPang(#); W Jing(#); P Liu; T Wu;C Cai; J Shi; Z Qin; H Yin; C Qiu; C Li; YXia; W Chen; Z Ye; Z Li; G Chen; SWang; Y Liu; L Chu; M Zhu; T Xu; Q Wang; JWang; Y Du; J Wang; N Chu(*); SXu(*).Clofazimine improves clinical outcomes inmultidrug-resistanttuberculosis: a randomized controlled trial. ClinicalMicrobiology andInfection. 2019,25(2):190-195.SCI

38. Li X #, Deng Y , Wang J , Jing H , ShuW , Qin J , Pang Y *, Ma X*..Rapid Diagnosis Of Multidrug-ResistantTuberculosis Impacts ExpendituresPrior To Appropriate Treatment: A PerformanceAnd Diagnostic Cost Analysis..Infect Drug Resist. . 2019,Nov14;12:3549-3555.SCI

39. Yaoju Tan#, Biyi Su, Xingshan Cai, PingGuan, Xin Liu, Pinyun Ma,Huilin Zhou, Jianxiong Liu*, Yu Pang*.An automatedsmear microscopy system todiagnose tuberculosis in a high-burden setting..Clin Microbiol Infect.2019,25(12):1553-1559.SCI

40. Yu Pang(#); Jun An(#); Wei Shu(#);Fengmin Huo; Naihui Chu;Mengqiu Gao;Shibing Qin; Hairong Huang; Xiaoyou Chen;Shaofa Xu(*).Epidemiologyof Extrapulmonary Tuberculosis among Inpatients,China, 2008-2017. Emerg InfectDis. 2019,25(3):457-464.SCI

41. Tang Peijun(#); Xu Ping(#); Shu Wei;Wang Xiafang; Guo Jian; SongHuafeng; Li Sumei; Pang Yu(*); Wu Meiying(*).Additional benefits of GeneXpertMTB/RIF assay for the detection of pulmonarytuberculosis patients with priorexposure to fluoroquinolones.. Infection andDrug Resistance. 2019,12:87-93.SCI

42. Jin Shi#,Jie Lu#,Shu'an Wen#,ZhaojingZong,Fengmin Huo,JingjingLuo,Qian Liang,Yunxu Li,Hairong Huang*,Yu Pang*.InVitro Activity of PBTZ169against Multiple Mycobacterium Species.. AntimicrobAgents Chemother.2018,62(11):e01314-18.

43. Tan Y(#); Su B(#); Shu W; Cai X; KuangS; Kuang H; Liu J(*); PangY(*).Epidemiology of pulmonary disease due tonontuberculous mycobacteria in SouthernChina, 2013-2016. BMC PulmonaryMedicine. 2018,18:168.SCI

44. Kang Wanli(#); Wu Meiying; Yang Kunyun;Ertai A; Wu Shucai; GengShujun;Li Zhihui; Li Mingwu; Pang Yu(*); TangShenjie(*).Factors associated withnegative T-SPOT.TB results amongsmear-negative tuberculosis patients in China..Scientific Reports.2018,8(1):0-4236 .SCI

45. Ma Y(#); Pang Y(#); Shu W(#); Liu Y H;Ge Q P; Du J(*); Li L(*);Gao W W(*).Metformin reduces the relapse rate oftuberculosis patients withdiabetes mellitus: experiences from 3-yearfollow-up. European Journal ofClinical Microbiology & Infectious Diseases.2018,37(7):1259-1263.SCI

46. Wu Xiaoguang(#); Pang Yu(#); SongYanhua(#); Dong Wenzhu; ZhangTingting;Wen Shuan; Huang Hairong(*); GaoMengqiu(*). Implications of a schooloutbreak of multidrug-resistanttuberculosis in Northern China.. Epidemiologyand Infection. 2018,146(5):584-588.SCI

47. Xu Caihong(#); Pang Yu(#); LiRenzhong(#); Ruan Yunzhou; WangLixia; Chen Mingting; Zhang Hui(*).Clinicaloutcome of multidrug-resistanttuberculosis patients receiving standardizedsecond-line treatment regimen inChina.. Journal of Infection.2018,76(4):348-353.SCI

48. Zhang Z(#); Lu J(#); Song Y; PangY(*).In vitro activity betweenlinezolid and other antimicrobial agents againstMycobacterium abscessuscomplex. Diagn Microbiol Infect Dis.2018,90(1):31-34.SCI

49. Xu P(#); Pang Y(#); Xu J; Chen H; TangP; WuM(*),.Cytokine-induced killer cell therapy as a promisingadjunctiveimmunotherapy for multidrug-resistant pulmonary TB: a casereport.Immunotherapy. 2018,10(10):827-830.SCI

50. Huo Fengmin(#); Luo Jingjing(#); ShiJin; Zong Zhaojing; JingWei; Dong Wenzhu; Dong Lingling; Ma Yifeng; LiangQian; Shang Yuanyuan; HuangHairong(*);Pang Yu(*).A 10-Year ComparativeAnalysis Shows that IncreasingPrevalence of Rifampin-Resistant Mycobacteriumtuberculosis in China IsAssociated with the Transmission of Strains HarboringCompensatory Mutations.Antimicrobial Agents and Chemotherapy.2018,62(4):e02303-17.SCI

51. Shi Jin(#); Dong Wenzhu; Ma Yifeng;Liang Qian; Shang Yuanyuan;Wang Fen; Huang Hairong(*); Pang Yu(*).GeneXpertMTB/RIF OutperformsMycobacterial Culture in Detecting Mycobacteriumtuberculosis from SalivarySputum.. Biomed Research International.2018,2018:1514381.SCI

52. Wang Qingfeng(#); Pang Yu(#); JingWei(#); Liu Yufeng; Wang Na;Yin Hongyun; Zhang Qing; Ye Zhizhong; Zhu Min; LiFujian; Liu Ping; Wu Tingting;Chen Wei; Wu Wei; Qin Zhihua; Qiu Chao; DengQunyi; Xu Tao; Wang Jing; Guo Ru;DuYadong; Wang Jun; Huang Hairong(*); henXiaohong(*); Chu Naihui(*).Clofazimin efor Treatment of ExtensivelyDrug-Resistant Pulmonary Tuberculosis in China..Antimicrobial Agents andChemotherapy. 2018,62(4) :e02149-17.SCI

53. Zong Zhaojing(#); Huo Fengmin(#); ShiJin(#); Jing Wei; MaYifeng; Liang Qian; Jiang Guanglu; Dai Guangming; HuangHairong(*); Pang Yu(*).RelapseVersus Reinfection of Recurrent TuberculosisPatients in a National TuberculosisSpecialized Hospital in Beijing, China.Frontiers in Microbiology.2018,9:0-1858.SCI

54. Zong Zhaojing(#); Jing Wei(#); ShiJin(#); Wen Shu'an; ZhangTingting; Huo Fengmin; Shang Yuanyuan; Liang Qian;Huang Hairong(*); PangYu(*).Comparison of In Vitro Activity and MICDistributions between the NovelOxazolidinone Delpazolid and Linezolid againstMultidrug-Resistant andExtensively Drug-Resistant Mycobacterium tuberculosisin China. AntimicrobialAgents and Chemotherapy. 2018,62(8):e00165-18.SCI

55. An Jun(#); Bai Xuejuan(#); Gao Mengqiu;Chu Naihui; HuangHairong; Xu Hongyin; Zhang Xiuping; Li Baoxia; Huang Cailiu;Cai Haixia; ZhangFengqin; Pang Yu(*); Li Liang(*).Antituberculosis drugprescribing forinpatients in a national tuberculosis hospital in China,2011-2015.. J GlobAntimicrob Resist. 2018,14:17-22.SCI

56. Pang Y(#); Zhu D(#); Zheng H; Shen J;Hu Y; Liu J(*); ZhaoY(*).Prevalence and molecular characterization ofpyrazinamide resistance amongmultidrug-resistant Mycobacterium tuberculosisisolates from Southern China..BMC Infect Dis. 2017,17(1):711.SCI

57. Liu Z(#); Pan A(#); Wu B; Zhou L; He H;Meng Q; Chen S; PangY(*); Wang X(*).Feasibility of a new model for earlydetection of patients withmultidrug-resistant tuberculosis in a developedsetting of eastern China. TropMed Int Health. 2017,22(10):1328-1333.SCI

58. Pang Y(#)(*); Zong Z(#); Huo F; Jing W;Ma Y; Dong L; Li Y; ZhaoL; Fu Y;Huang H(*).In Vitro Drug Susceptibility ofBedaquiline, Delamanid,Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacinagainst ExtensivelyDrug-Resistant Tuberculosis in Beijing, China. AntimicrobAgents Chemother.2017,61(10):e00900-17.SCI

59. Pang Y(#); Shang Y(#); Lu J; Liang Q;Dong L; Li Y; Zhao L; JiangG;Huang H(*).GeneXpert MTB/RIF assay in thediagnosis of urinary tuberculosisfrom urine specimens. Sci Rep.2017,7(1):6181.SCI

60. Tan Y(#); Li Q(#); Wang Q(#); Sun H(#);Chen J; Cai X; Yao Y; BaoX; Wang C; Liu Y; Wu X; Pang Y(*); ZhaoY(*).Evaluation of the MTBDRplus 2.0assay for the detection of multidrugresistance among persons with presumptivepulmonary TB in China. Sci Rep.2017,7(1):3364.SCI

61. Ma Y(#); Pang Y(#); Du J(#); Liu Y; LiL(*); Gao W(*).Clinicaloutcomes for multi- and extensively drug resistanttuberculosis patients withadjunctive resectional lung surgery in Beijing,China. J Thorac Dis.2017,9(3):841-845.SCI

62. Zhang, Zhijian(#); Lu, Jie(#); Liu,Min(#); Wang, Yufeng; Zhao,Yanlin(*);Pang, Yu(*).In vitro activity ofclarithromycin in combination withother antimicrobial agents againstMycobacterium abscessus and Mycobacteriummassiliense.. International Journalof Antimicrobial Agents,.2017,49(3):383-386.SCI

63. Pang, Yu(#); Zhang, Zhijian(#); Wang,Yufeng; Wang, Shengfen;Song, Yuanyuan; Zhao, Bing; Zhou, Yang; Ou, Xichao; Li,Qiang; Xia, Hui; Zheng,Yang;Fang, Xiangqun(*); Zhao, Yanlin(*).Genotyping andPrevalence ofPyrazinamide-and Moxifloxacin-Resistant Tuberculosis in China,2000 to 2010..Antimicrobial Agents and Chemotherapy. 2017,61(2):e02170-16.SCI

64. Wang, Li(#); Zhang, Zhiguo(#); Yan,Qiuli(#); Lu, Jie; Gao,Baoyin; Zhao, Yanlin; Pang, Yu(*).Diagnostic dilemma ofpulmonary tuberculosisamong adults with severe mental illness in Beijing,hina.. BMC InfectiousDiseases. 2017,17(1):83.SCI

65. Chen L(#); Pang Y(#); Ma L; Yang H; RuH; Yang X; Yan S; Jia M;Xu L(*).First Insight into the Molecular Epidemiologyof Mycobacteriumtuberculosis Isolates from the Minority Enclaves ofSouthwestern China. BiomedRes Int. 2017,2017:2505172.SCI

66. Han Xi Qin(#); Pang Yu(#); Ma Yan(#);Liu Yu Hong; Guo Ru; ShuWei; Huang Xue Rui; Ge Qi Ping; Du Jian(*); Gao WeiWei(*) .Prevalence and RiskFactors Associated with Adverse Drug Reactionsamong Previously TreatedTuberculosis Patients in China. 生物医学与环境科学(英文版). 2017,30(2):139-142.SCI

67. Pang Y(#)(*); Zheng H(#); Tan Y; SongY; Zhao Y(*).In vitroactivity of bedaquiline against nontuberculousmycobacteria in China. AntimicrobAgents Chemother. 2017,61(5):e02627-16.SCI

68. Pang, Yu(#); Tan, Yaoju(#); Chen,Jin(#); Li, Yanming(#); Zheng,Huiwen;Song, Yuanyuan; Zhao, Yanlin(*).Diversityof nontuberculous mycobacteriain eastern and southern China: a cross-sectionalstudy. European RespiratoryJournal. 2017,49(3):1601429.SCI

69. Pang Y(#); Lu J(#); Huo F; Ma Y; ZhaoL; Li Y; Liang Q; Chu N(*);Gao M(*);Huang H(*).Prevalence and treatmentoutcome of extensivelydrug-resistant tuberculosis plus additional drugresistance from the NationalClinical Center for Tuberculosis in China: Afive-year review. J Infect. 2017,75(5):433-440.SCI

70. Jing W(#); Pang Y(#); Zong Z; Wang J;Guo R; Huo F; Jiang G; MaY; Huang H(*); Chu N(*).Rifabutin ResistanceAssociated with Double Mutations inrpoB Gene in Mycobacterium tuberculosisIsolates. Front Microbiol.2017,14(8):1768.SCI

71. Tan Y(#); Su B; Zheng H; Song Y; WangY; Pang Y(*).MolecularCharacterization of Prothionamide-ResistantMycobacterium tuberculosis Isolatesin Southern China. Front Microbiol.2017,8(1):2358.SCI

72. Xie ZY(#); Huang GF; Gao H; Chi YQ;Wang YX; Pang Y(*); Wang JP(*).NosocomialInfection Surveillance in aTuberculosis Specialized Hospital in China. BiomedEnviron Sci.2017,30(9):691-694.SCI

73. Pang Y(#)(*); Lu J(#); Su B; Zheng H;Zhao Y(*).Misdiagnosis oftuberculosis associated with some species ofnontuberculous mycobacteria byGeneXpert MTB/RIF assay. Infection.2017,45(5):677-681.SCI

74. Du, Jian(#); Pang, Yu(#); Ma, Yan(#);Mi, Fengling; Liu, Yuhong;Li,Liang(*).Prevalence of tuberculosis among healthcare workers in tuberculosisspecialized hospitals in China.. Journal ofOccupational Health.2017,59(3)::292-295.SCI

75. Tan Y(#); Su B; Zheng H; Wang Y; PangY(*).Prothionamidesusceptibility testing of Mycobacterium tuberculosis usingthe resazurinmicrotitre assay and the BACTECMGIT 960 system. Eur J ClinMicrobiol Infect Dis.2017,36(5):779-782.SCI

76. Pang Y(#); Du J(#); Qin ZZ(#);Greenwald Z; Liu Y; Mi F; Zhao Y;Li L(*).An overview on tuberculosis-specifichospitals in China in 2009: Resultsof a national survey. Eur Respir J.2016,47(5):1584-1587.SCI

77. Li, Yanming(#); Pang, Yu(#); Tong,Xunliang; Zheng, Huiwen; Zhao,Yanlin(*); Wang, Chen(*).Mycobacterium kansasiiSubtype I Is Associated WithClarithromycin Resistance in China.. Frontiers inMicrobiology.2016,7:2097-2097.SCI

78. Wang, Ting(#); Feng, Guo-Dong(#); Pang,Yu(#); Yang, Yi-Ning;Dai, Wen; Zhang, Lin; Zhou, Lin-Fu; Yang, Jia-Lei; Zhan,Li-Ping; Marais, Ben J;Zhao,Yan-Lin(*); Zhao, Gang(*).Sub-optimal Specificityof Modified Ziehl-NeelsenStaining for Quick Identification of Tuberculous Meningitis..Frontiers inMicrobiology. 2016,7:2096.SCI

79. Pang, Yu(#); Su, Biyi(#); Zheng,Huiwen; Zhang, Zhiguo; Ma,Aijing;Wang, Yufeng; Zhao, Yanlin(*).FactorsAssociated with Missed Detection ofMycobacterium tuberculosis by AutomatedBACTEC MGIT 960 System.. Biomed ResearchInternational. 2016,2016:5972021.SCI

80. Zhang, Dan(#); Wang, Yufeng; Lu, Jie;Pang, Yu(*).In VitroActivity of beta-Lactams in Combination withbeta-Lactamase Inhibitors againstMultidrug-Resistant Mycobacteriumtuberculosis Isolates. Antimicrobial Agentsand Chemotherapy.2016,60(1):393-399.SCI

81. Liu, Zhengwei(#); Pang, Yu(#); Chen,Songhua; Wu, Beibei; He,Haibo;Pan, Aizhen; Wang, Xiaomeng(*).A First Insightinto the Genetic Diversityand Drug Susceptibility Pattern of Mycobacteriumtuberculosis Complex inZhejiang, China.. Biomed Research International.2016,2016:8937539.SCI

82. Liqun Zhang(#); Yu Pang(#); Xia Yu(#);Yufeng Wang; Jie Lu;Mengqiu Gao(*); Hairong Huang(*); Yanlin Zhao(*),.Riskfactors for pulmonarycavitation in tuberculosis patients from China. EmergMicrobes Infect.2016,5(10):e110.SCI

83. An, Jun(#); Gao, Mengqiu; Chu, Naihui;Huang, Hairong; Pang,Yu(*); Li,Liang(*).Transregional movement ofmultidrug-resistant tuberculosis innorth China: an underlying threat totuberculosis control.. Scientific Reports.2016,6:29727.SCI

84. Pang, Yu(#); Dong, Haiyan(#); Tan,Yaoju(#); Deng, Yunfeng(#);Cai, Xingshan; Jing, Hui; Xia, Hui; Li, Qiang; Ou,Xichao; Su, Biyi; Li,Xuezheng;Zhang, Zhiying; Li, Junchen; Zhang, Jiankang;Huan, Shitong; Zhao,Yanlin(*).Rapid diagnosis of MDR and XDR tuberculosis withthe MeltPro TB assayin China.. Scientific Reports. 2016,6:25330.SCI

85. Pang, Yu(#); Zhao, Aihua(#); Cohen,Chad; Kang, Wanli; Lu, Jie;Wang,Guozhi; Zhao, Yanlin; Zheng, Suhua(*).Currentstatus of new tuberculosisvaccine in children.. Hum Vaccin Immunother.2016,12(4):960-970.SCI

86. Wang T(*); Feng GD(#); Pang Y(#); LiuJY; Zhou Y; Yang YN; Dai W;Zhang L; Li Q; Gao Y; Chen P; Zhan LP; Marais BJ;Zhao YL(*); Zhao G(*).Highrate of drug resistance among tuberculous meningitiscases in Shaanxi province,China,. Sci Rep. 2016,6:25251.SCI

87. Yu Pang(#)(*); Zhongdong Wang(#);Huiwen Zheng; Yuanyuan Song;Yufeng Wang; Yanlin Zhao(*).Pyrazinamideresistance determined by liquid cultureat low pH better correlates withgenetic mutations in MDR tuberculosis isolates.Journal of MicrobiologicalMethods. 2015,119(12):142-144.SCI

88. Du, Jian(#); Emilio, Dirlikov(#); Pang,Yu(#); Ma, Yan; Mi,Fengling;Liu, Yuhong; Li, Liang(*).TuberculosisHospitalization Fees and BedUtilization in China from 1999 to 2009: TheResults of a National Survey ofTuberculosis Specialized Hospitals.. PLos One.2015,10(10):e0139901.SCI

89. Pang, Yu(#); Zhou, Yang(#); Wang,Shengfen; Song, Yuanyuan; Ou,Xichao;Zhao, Bing; Zhang, Zhijian; Zhao,Yanlin(*),.Prevalence and risk factorsof mixed Mycobacterium tuberculosiscomplex infections in China.. Journal ofInfection. 2015,71(2):231-237.SCI

90. Zhang, Zhijian(#); Pang, Yu(#)(*);Wang, Yufeng; Cohen, Chad;Zhao,Yanlin(*); Liu, Changting(*).Differences inrisk factors and drugsusceptibility between Mycobacterium avium andMycobacterium intracellulare lungdiseases in China.. International Journal ofAntimicrobial Agents.2015,45(5):491-495.SCI

91. Yang, Xiujun(#); Yuan, Yanli(#); Pang,Yu(#); Wang, Bo; Bai,Yunlong;Wang, Yanhua; Yu, Baozhu; Zhang, Zhiying; Fan,Ming(*); Zhao,Yanlin(*).The burden of MDR/XDR tuberculosis in coastal plainspopulation ofChina.. PLos One. 2015,10(2):e0117361.SCI

92. Zou, Lin(#); Liu, Min; Wang, Yufeng;Lu, Jie; Pang,Yu(*).Determination of in vitro synergy between linezolid andotherantimicrobial agents against Mycobacterium tuberculosis isolates..Tuberculosis(Edinb). 2015,95(6):839-842.SCI

93. Pang, Yu(#); Lu, Jie(#); Yang, Jian; Wang,Yufeng; Cohen, Chad;Ni, Xin(*); Zhao, Yanlin(*).A novel method for diagnosisof smear-negativetuberculosis patients by combining a random unbiased Phi29amplification with aspecific real-time PCR. Tuberculosis (Edinb).2015,95(4):411-414.SCI

94. Pang, Yu(#); Kang, Wanli(#); Zhao,Aihua(#); Liu, Guan; Du,Weixin; Xu,Miao; Wang, Guozhi(*); Zhao, Yanlin(*);Zheng, Suhua(*).The effect ofbacille Calmette-Guerin vaccination at birth onimmune response in China..Vaccine. 2015,33(1):209-213.SCI

95. Zhang, Zhijian(#); Li, Tianzhi(#); Qu,Geping; Pang, Yu(*); Zhao,Yanlin(*).In vitro synergistic activity ofclofazimine and other antituberculousdrugs against multidrug-resistantMycobacterium tuberculosis isolates..Internation al Journal of AntimicrobialAgents. 2015,45(1):71-75.SCI

96. Zhijian Zhang(#); Jie Lu(#); YufengWang; Yu Pang(*); YanlinZhao(*).Automated liquid culture system missesisoniazid heteroresistance inMycobacteriumtuberculosis isolates with mutationsin the promoter region of theinhA gene. Eur J Clin Microbiol Infect Dis.2015,34(3):555-560.SCI

97. Zhang, Zhijian(#); Lu, Jie(#); Liu,Min(#); Wang, Yufeng; Qu,Geping; Li,Hongxia; Wang, Jichun; Pang, Yu(*); Liu,Changting(*); Zhao,Yanlin(*).Genotyping and molecular characteristics ofmultidrug-resistantMycobacterium tuberculosis. Journal of Infection.2015,70(4):335-345.SCI

98. Zhijian Zhang#,Jie Lu#,Min Liu#,YufengWang,Geping Qu,HongxiaLi,Jichun Wang,Yu Pang*,Changting Liu*,YanlinZhao*.Genotyping and molecularcharacteristics of multidrug-resistantMycobacterium tuberculosis isolates fromChina. J Infect.2015,70(4):335-345.SCI

99. Yu Pang#,Jian Du#,Zhi Ying Zhang,XiChao Ou,Qiang Li,Hui Xia,YanQu*,Yan Lin Zhao*.The feasibility of sputumtransportation system in China:effect of sputum storage on the mycobacterialdetection. Biomed Environ Sci.2015,27(12):982-986.SCI

三、主编或副主编的著作/译著

1. 《结核病实验室检验规程》,主编,人民卫生出版社,201506